Current disease phase-Chronic phase Posts on Medivizor
Navigation Menu

Current disease phase-Chronic phase Posts on Medivizor

Can molecular response to imatinib indicate treatment response in patients with chronic myeloid leukemia?

Posted by on Feb 20, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated if the molecular response to Imatinib (Gleevec) is a proper way to judge treatment progress in Iranian patients with chronic-phase chronic myeloid leukemia (CP-CML). The main finding was that survival was improved in patients who had a better molecular response to imatinib. Some background Patients with...

Read More

Which factors affect the safety and effectiveness of imatinib treatment for newly diagnosed chronic myeloid leukemia?

Posted by on Jan 7, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of imatinib treatment in patients with newly diagnosed chronic myeloid leukemia. This study concluded that patients of lower weight and older age are more vulnerable to side effects.  Some background Imatinib (Gleevec) is a targeted therapy...

Read More

Are the currently prescribed doses of tyrosine kinase inhibitors too high for elderly patients with chronic myeloid leukemia?

Posted by on Dec 15, 2019 in Leukemia | 0 comments

In a nutshell This study investigated the prescribed doses of tyrosine kinase inhibitors (TKIs) and the outcomes of elderly patients with chronic myeloid leukemia (CML). The study concluded that the currently prescribed TKI dose might be higher than necessary in elderly patients. Some background TKIs such as imatinib (Glivec), dasatinib...

Read More

Outcomes od BCR-ABL mutated chronic myeloid leukemia patients who have failed tyrosine kinase inhibitors

Posted by on Aug 16, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the frequency of BCR-ABL kinase domain mutation detection and its prognostic significance in patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs).  This study concluded that early mutation detection and use of 2nd and...

Read More

Safety and effectiveness of unbranded imatinib in CML

Posted by on Oct 19, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the safety and effectiveness of switching from original brand imatinib (Gleevec) to generic imatinib in chronic myeloid leukemia (CML). The study found that switching from branded to generic imatinib is a safe option in these patients. Some background New medications on the market have a patent by their...

Read More

Evaluating nilotinib as a consolidation therapy for patients with chronic myeloid leukemia

Posted by on Sep 8, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the effectiveness of nilotinib as a consolidation therapy for patients with chronic myeloid leukemia who had achieved a major response with imatinib. This study concluded that nilotinib led to safer, deeper responses in these patients. Some background Imatinib (Gleevec) is a tyrosine kinase inhibition (TKI)...

Read More